GRPH - Recently IPO'ed Graphite Bio and Verve join gene-editing rally

Andy/iStock via Getty Images The strength of gene-editing space has benefited even the recently IPO’ed companies in the subsector even though their assets have yet to reach the clinical stage. The rally began after Intellia and Regeneron disclosed interim results from a Phase 1 trial for transthyretin amyloidosis ((ATTR)) candidate NTLA-2001 indicating the safety and efficacy of in-vivo CRISPR genome editing for the first time in humans. Meanwhile, recently IPO’ed Verve Therapeutics ([[VERV]] +24.8%) focused on cardiovascular disease with single-course gene-editing therapies is on course to post its best one-day gain since its public debut on June 17. The firm's lead candidate, VERVE-101 is currently in the pre-clinical stage for heterozygous familial hypercholesterolemia. Meanwhile, Graphite Bio ([[GRPH]] +20.4%) which added ~8.8% to the IPO price on its first day of trading has climbed more than a fifth today. The company with a gene-editing approach based on CRISPR technology has its lead asset

For further details see:

Recently IPO’ed Graphite Bio and Verve join gene-editing rally